source
- Paragon Labs hires former Apogee leadership after AbbVie acquisition and spins out hypertension unitParagon Labs announced it has brought several former Apogee Therapeutics executives onto its senior team following AbbVie's $10.9 billion purchase of Apogee. The incoming leaders include Michael H…
- Nurix halts development of BTK degrader zelebrudomide after phase 1 reviewNurix announced it will discontinue clinical development of its BTK degrader zelebrudomide, also known as NX-2127, following completion of enrollment in a phase 1 trial for aggressive non‑Hodgkin l…